Ozge Gumusay (O Gumusay)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 7

Top Topics

Metastatic Breast Cancer

Smoking Cessation

Top Venues

Future oncology (London, England)

Breast cancer research and treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers. Immunotherapy (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer? Future oncology (London, England) 18 (39) (2023)
Ozge Gumusay, J Callan, H S Rugo
Immunotherapy toxicity: identification and management. Breast cancer research and treatment 192 (1) (2022)
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer. Future oncology (London, England) 18 (9) (2022)